By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Insider activity at Puma Biotechnology, Inc. has been all selling for a year now: about $2.1 million from ten sellers, and zero buyers with their own money.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
Looking at the quarterly pattern: 7 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters. On the institutional side, 161 funds reported holding PBYI at the end of Q2 2026, and more funds bought than sold.
Are insiders buying or selling PBYI stock?
In the last 12 months Puma Biotechnology, Inc. insiders made open-market purchases worth about $0 and sales worth about $2.1 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in PBYI?
The most recent open-market insider trade in PBYI was filed on 2026-09-16.
How many institutions own PBYI?
161 investment managers reported holding PBYI in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded PBYI?
No congressional trades in PBYI were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).